Gilead Sciences, Inc. (GILD) Earnings Call Transcripts

Gilead Sciences, Inc.'s Latest Earnings Call - September 15, 2026

In the third quarter of fiscal year 2026, Gilead Sciences reported strong performance driven by its HIV portfolio and new product launches, particularly Yeztugo, which is expected to generate $1 billion in its first year. The company maintained its revenue guidance, projecting a 10% growth for its HIV segment, up from previous estimates. Overall, Gilead's robust pipeline, including upcoming oncology therapies, positions it well for future growth, potentially impacting stock performance positively.

Reported metrics

Guidance from management

Gilead maintained its HIV growth guidance at 10%, signaling confidence in its product pipeline and market recovery. The company also expects significant contributions from Yeztugo and upcoming oncology launches.

What management said

Still too early a little bit. what we are seeing is definitely that people need to find their path. And we've seen it even -- in the second quarter, we also had a little bit of a bump because of Florida ADAP, and we've seen that lease that right away. So I do think that since Florida ADAP, then we reinstated Descovy on its formulary in July. I think that's been a great opportunity for patients to get back on their bi...

Absolutely. Because of that market expansion play that we talked about earlier, I think depending on the option that we're referring to, but as a totality, most of them are all additive to the current market today for a couple of reasons. One is just execution on the market, increased awareness. And 2 is sometimes different populations that are coming through, let alone the compliance that you're going to get with ...

What analysts pressed on

Analysts expressed concerns about the competitive landscape in immunology and the potential impact of regulatory pressures on pricing. There is also caution regarding the sustainability of growth in the HIV market amid changing healthcare policies.

Main topics on the call

• Yeztugo Launch Success — Gilead's Yeztugo launch has exceeded expectations, with management stating, "We're now expecting our guidance is at $1 billion for its first full year of launch." The product has seen a balanced mix of new users and swit...
• HIV Portfolio Diversification — Management highlighted the ongoing transition in the HIV franchise, stating, "We're in the middle of kind of transitioning the entirety of our HIV franchise across both treatment and prevention." This diversification is ...
• Oncology Pipeline Development — Gilead is preparing for the launch of a new oncology product, with management noting, "A needle cell is the most imminent launch in oncology of a new molecular entity in fourth line plus multiple myeloma." This reflects ...
• Guidance Update for HIV Growth — The company raised its guidance for HIV growth from 8-9% to 10%, with management stating, "We believe that we can more than cover that." This indicates confidence in the market recovery and product performance.

Read the full Gilead Sciences, Inc. transcript (September 15, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 117 Gilead Sciences, Inc. earnings call transcripts on record, spanning January 13, 2020 to September 15, 2026. Based on this history, Gilead Sciences, Inc. reports quarterly. The most recent call on file is dated September 15, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

GILD

Exchange

NasdaqGS

Country

US

Sector

Health Care

Industry

Biotechnology

Calls on record

117

First call

January 13, 2020

Most recent

September 15, 2026

Reporting cadence

quarterly